RR and RD results for comparisons of treatment intensity pairs
| Outcome | Placebo – moderate Intensity | Moderate – high Intensity | Placebo – high Intensity | ||||||
| RR (95% CI) | RD (95% CI) | NNH | RR (95% CI) | RD (95% CI) | NNH | RR (95% CI) | RD (95% CI) | NNH | |
| Any probs | 1.010 (0.988 to 1.033) | 0.000 (−0.001 to 0.001) | – | 1.039 (1.004 to 1.075) | 0.004 (−0.000 to 0.008) | – | 1.049 (1.010 to 1.089) | 0.004 (−0.001 to 0.008) | – |
| Myalgia | 1.090 (0.9997 to 1.188) | 0.001 (−0.000 to 0.001) | – | 1.041 (1.001 to 1.083) | 0.006 (0.001 to 0.010) | 173 | 1.134 (1.046 to 1.230) | 0.007 (0.002 to 0.011) | 182 |
| Attrition | 1.127 (0.931 to 1.364) | 0.001 (−000 to 0.001) | – | 1.372 (1.091 to 1.726) | 0.005 (0.002 to 0.007) | 218 | 1.155 (1.147 to 2.084) | 0.005 (0.002 to 0.008) | 187 |
| Rhabdomyolysis | 1.225 (0.624 to 2.405) | −0.000 (−0.001 to 0.001) | – | 1.326 (0.487 to 3.614) | 0.002 (0.001 to 0.003) | – | 1.624 (0.579 to 4.553) | 0.002 (0.000 to 0.003) | – |
| CK >10 × ULN | 1.143 (0.686 to 1.905) | −0.000 (−0.001 to 0.001) | – | 4.594 (2.320 to 9.098) | 0.002 (0.001 to 0.003) | 527 | 5.252 (2.293 to 12.028) | 0.002 (0.000 to 0.003) | 589 |
NNH, number needed to harm; RD, risk difference; RR, relative risk.